» Articles » PMID: 24961377

Aspirin-intolerant Asthma in the Population: Prevalence and Important Determinants

Overview
Date 2014 Jun 26
PMID 24961377
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Population-based studies on aspirin-intolerant asthma (AIA) are very few, and no previous population study has investigated risk factors for the condition.

Objective: To investigate the prevalence and risk factors of AIA in the general population.

Methods: A questionnaire on respiratory health was mailed to 30,000 randomly selected subjects aged 16-75 years in West Sweden, 29,218 could be traced and 18,087 (62%) responded. The questionnaire included questions on asthma, respiratory symptoms, aspirin-induced dyspnoea and possible determinants.

Results: The prevalence of AIA was 0.5%, 0.3% in men and 0.6% in women (P = 0.014). Sick leave, emergency visits due to asthma and all investigated lower respiratory symptoms were more common in AIA than in aspirin-tolerant asthma (ATA). Obesity was a strong risk factor for AIA (BMI > 35: odds ratio (OR) 12.1; 95% CI 2.49-58.5), and there was a dose-response relationship between increasing body mass index (BMI) and risk of AIA. Obesity, airborne occupational exposure and visible mould at home were considerably stronger risk factors for AIA than for ATA. Current smoking was a risk factor for AIA (OR 2.55; 95% CI 1.47-4.42), but not ATA.

Conclusion: Aspirin-intolerant asthma identified in the general population was associated with a high burden of symptoms, uncontrolled disease and a high morbidity. Increasing BMI increased the risk of AIA in a dose-response manner. A number of risk factors, including obesity and current smoking, were considerably stronger for AIA than for ATA.

Citing Articles

[Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs (2024, Chengdu)].

Meng J, Ye J, Zhang L, Xu Y, Liu W, Yang Y Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(6):453-462.

PMID: 38858107 PMC: 11480570. DOI: 10.13201/j.issn.2096-7993.2024.06.001.


Risk factors of NSAID-exacerbated respiratory disease: A population-based study.

Heleva A, Murtomaki A, Huhtala H, Bousquet J, Luukkainen A, Karjalainen J Clin Transl Allergy. 2023; 13(8):e12296.

PMID: 37632242 PMC: 10442774. DOI: 10.1002/clt2.12296.


Polymorphisms in Human , , and Genes Are Associated with an Increased Risk of Developing NSAID-Exacerbated Respiratory Disease.

Reigada-Rivera M, Lozano C, Rodilla E, Garcia-Sanchez A, Garcia-Solaesa V, Toledano F Genes (Basel). 2022; 13(4).

PMID: 35456412 PMC: 9031626. DOI: 10.3390/genes13040605.


Cilostazol combined with P2Y receptor inhibitors: A substitute antiplatelet regimen for aspirin-intolerant patients undergoing percutaneous coronary stent implantation.

Zhao Y, Zhou P, Gao W, Zhong H, Chen Y, Chen W Clin Cardiol. 2022; 45(2):189-197.

PMID: 35120275 PMC: 8860475. DOI: 10.1002/clc.23787.


NSAID-exacerbated respiratory disease: a population study.

Andersen H, Ilmarinen P, Honkamaki J, Tuomisto L, Hisinger-Molkanen H, Backman H ERJ Open Res. 2022; 8(1).

PMID: 35083326 PMC: 8784895. DOI: 10.1183/23120541.00462-2021.